← Back to all trials
Active Not Recruiting
NCT06557148
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer
Conditions: Breast Cancer, Lobular Breast Carcinoma, Breast Carcinoma, Metastatic Breast Cancer, Metastatic Lobular Breast Carcinoma, Metastatic Breast Carcinoma
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 7
Sponsor: Memorial Sloan Kettering Cancer Center
Location: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) Basking Ridge New Jersey
Summary
The purpose of this study to compare two types of cancer imaging scans to see which is better at detecting and monitoring metastatic ILC. This study will compare PET/CT (positron emission tomography/computed tomography) scans using the radiotracer fluorine 18 (18F)-fluoroestradiol (FES) with a standard imaging approach for detecting and monitoring ILC, PET/CT scans using the radiotracer 18F-fluorodeoxyglucose (FDG). These scans will be referred to as FES PET/CT scans and FDG PET/CT scans.
Eligibility Criteria
Inclusion Criteria:
* Adult patient \> 18 years old
* Biopsy-proven metastatic ILC
* Confirmed ER+ breast cancer from either primary tumor or metastatic biopsy (ER receptor percent staining ≥ 10% of tumor cells by IHC)
* HER2-negative per ASCO/CAP
* ECOG Performance Status Score of 0, 1 or 2.
* Patient can have received up to 2 lines of therapy in the metastatic setting
* Life expectancy of at least 12 months
Exclusion Criteria:
* Low ER expression defined as ER \
Source: ClinicalTrials.gov (NCT06557148). StuddyBuddy aggregates publicly available trial information.
